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Abstract
Background and objective
Lipocalin-2 (LCN-2) is an adipokine that plays a protective role in various inflammatory
disorders and regulates innate immune response to acute and chronic infections. However,
scant information is available regarding the relationship between serum LCN-2 levels and type
2 diabetes mellitus (T2DM) occurring concurrently with chronic hepatic infections. The present
study sought to investigate the association of LCN-2 with T2DM patients with hepatic
infections.
Methods
The association of LCN-2 with T2DM, hepatic steatosis, and inflammation was tested in 37
non-T2DM noninfectious individuals (group A, control group) and 55 age-matched patients
with T2DM and chronic infection (group B). Anthropometric data were measured and the body-
fat percentage was calculated using bioelectrical impedance analysis (BIA). Hemoglobin (Hb),
fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), liver function enzymes (LFEs), lipid
profile, and total leukocyte count (TLC) were measured. Serum LCN-2 levels were measured
using a commercially available sandwich enzyme-linked immunosorbent assay method.
Results
Levels of LCN-2 were significantly elevated in group B (1896.90 ± 73.13 ng/ml) versus control
group A (263.58 ± 15.66 ng/mL; p<0.001). LCN-2 correlated moderately with alanine
aminotransferase (ALT) (r=0.369), alkaline phosphatase ALP (r=0.419), and HbA1c (r=0.341)
(p<0.01). All correlations were lost when adjusted for the presence of hepatitis, indicating that
liver infection exacerbates insulin resistance.
Conclusion
Based on our findings, circulating LCN-2 is elevated in T2DM subjects with hepatitis B co-
infection and may contribute towards deranged inflammatory response.
Categories: Endocrinology/Diabetes/Metabolism, Infectious Disease
Keywords: lipocalin, obesity, hepatitis, diabetes
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Metabolic syndrome (MetS) is a group of disorders that encompasses hypertension, cellular
resistance to insulin, central obesity, dyslipidemia, and pro-thrombotic inflammatory states [1].
These disorders are all usually interconnected, and they increase the risk of contracting
cardiovascular diseases (CVDs). Although there are several definitions for MetS, those
enumerated by the World Health Organization (WHO), the National Cholesterol Education
Program’s Third Adult Treatment Panel (NCEP-ATP III), and the International Diabetes
Foundation (IDF) are the most widely used and accepted ones [1-2]. The NCEP-ATP III
definition has been proposed to be superior to all other existing definitions in diagnosing MetS
and, as such, is now the most frequently adopted definition [2]. Worldwide, the prevalence of
MetS varies from as low as <10% to as high as >84% based on geographical location, with
approximately 25% of the world’s population estimated to be affected by the condition [3].
Therefore, the disease is a major contributor to mortality and general ill-health across the
globe. In particular, densely populated Asian countries such as China and India suffer from a
high prevalence of MetS. Several studies have been conducted in Pakistan over the years to
investigate the prevalence of MetS, out of which a study conducted in 2004 in Karachi, the
largest metropolitan area of Pakistan, found a prevalence of 49% in a sample size of 360 [4].
Additionally, four other separate studies have reported a MetS prevalence of 14.95%, 35%,
63.7%, and 22.95%, respectively, making Pakistan one of the countries most affected by MetS
worldwide [5-8].
Similar to MetS, type 2 diabetes mellitus (T2DM) is a vast mixture of interconnected metabolic
disorders that includes insulin resistance, unique dyslipidemia, obesity, and hyperglycemia [9],
with the most common etiological factor being obesity [10], which results in an increased blood
glucose concentration [11]. A systematic review conducted in December 2016 to investigate the
disease burden and prevalence of T2DM in both rural and urban areas of Pakistan reported a
mean prevalence of 11.7% with the prevalence being greater in men than in women and higher
in urban than in rural areas [12]. Hence, it is evident that the disease burden of T2DM needs to
be controlled in order to reduce the prevalence of a disorder that is leading to severe
complications and directly contributing to the prevalence of MetS. The pathophysiology behind
MetS is an impaired response of the body to insulin, which normally suppresses the production
of glucose and very-low-density lipoprotein (VLDL) [13]. This impairment causes substantial
changes in the liver, leading to numerous complications. Hepatic fibrosis occurs due to the
overproduction of glucose, cholesterol, and VLDL, which, if left untreated, can eventually lead
to steatohepatitis and hepatic cirrhosis [14].
Lipocalins (LCN) are a diverse family of minuscule extracellular secreted proteins that were
thought to function as transport proteins in the past. They show great diversity in structure and
have now been recognized to participate in a variety of functions including macromolecular
complexation, pheromone activity, olfaction, gustation, coloration, prostaglandin synthesis,
immune modulation, cell regulation, and as carrier proteins in the clearance of exogenous and
endogenous compounds [15]. Our focus is on LCN-2 or neutrophil gelatinase-associated
lipocalin (NGAL), which is a glycoprotein derived from adipose tissue. It is also believed to be an
inflammatory modulator and contributes to metabolic homeostasis [16]. LCN-2 has been found
to be closely linked to obesity, increased blood glucose, and insulin resistance [17]. In addition,
it has also been found to be significantly higher during phases of liver injury [18]. This study
aimed to investigate the relationship between LCN-2 and hepatic infections in T2DM patients.
Materials And Methods
Study design and patient population
This study was conducted at the Aga Khan University (AKU) in collaboration with the diabetic
clinic of Jinnah Postgraduate Medical Centre (JPMC). Approval from institutional ethical
committees of AKU and JPMC was obtained before initiating the study (ERC-3597-BBS-17 and
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No.F.2.81-IRB/2017/GENL/419/JPMC, respectively). The study design was cross-sectional, for
which a total of 92 subjects were recruited, and these subjects were classified according to their
diabetic status. Non-T2DM and noninfectious individuals (n=37) were labeled as group A
(control group). while patients with T2DM and chronic infection (n=55) were labeled as group B
(disease group). To select the participants, a convenience sampling technique was employed.
Participants were only considered to have T2DM if the fasting plasma glucose (FPG) was either
more than or equivalent to 100 mg/dl and were considered infectious if the hepatitis B antigen
result was positive on patients' medical record cards. Patients with other etiologies of
infections (other than hepatic infections) were excluded from the study. Patients who presented
to the outpatient department of the diabetic clinic at JPMC and fulfilled the eligibility criteria
were enrolled after taking informed consent. Gender, age, weight, and height of the patients
were noted and body mass index (BMI) was calculated. Furthermore, body fat was calculated
using bioelectrical impedance analysis (BIA). A 10-ml venous blood sample was obtained from
each participant after a fasting period of 12-14 hours. Hemoglobin (Hb), hemoglobin A1c
(HbA1c), FPG, serum alanine transaminase (ALT), alkaline phosphatase (ALP), lipid profile, and
total leukocyte count (TLC) were measured by Hitachi/Cobas automated analyzer (Hitachi,
Tokyo, Japan/Roche, Basel, Switzerland). LCN-2 was measured by a sandwich enzyme-linked
immunosorbent assay method using LCN-2 (kit cat number 96581 Glory Science,
Belgium) (Figure 1).
FIGURE 1: Summary of materials and methods
PCR: polymerase chain reaction; BMI: body mass index; BIA: bioelectrical impedance analysis;
HbA1c: glycated hemoglobin
Sample size and statistical analysis plan
Calculations were done using OpenEpi version 3 software. At 95% confidence interval and 5%
absolute precision, the sample size was calculated to be 92 considering the prevalence of T2DM
in Pakistan and the anticipated frequency as 50% (unknown anticipated frequency). Data
obtained was coded in SPSS Statistics version 21 (IBM, Armonk, NY). Single data entry with
visual comparison was performed to minimize error. The distribution of continuous variables
was determined. Furthermore, the means and standard deviations were reported respectively.
For categorical variables, descriptive analysis was presented in terms of frequencies and
percentages. The Mann-Whitney U test for variables that were quantitative, Pearson Chi-
Square test for categorical variables, and the Pearson correlation were applied as appropriate.
Data were analyzed using SPSS Statistics version 21 and a p-value of less than 0.01 was
considered significant.
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Operational definition
The NCEP-ATP III criteria [1] defines MetS as the presence of any three of the following five
traits: 1. abdominal obesity defined as a waist circumference of ≥102 cm (40 in) in men and ≥88
cm (35 in) in women; 2. serum triglyceride levels of ≥150 mg/dL (1.7 mmol/L) or drug treatment
for elevated triglycerides; 3. serum high-density lipoprotein (HDL) cholesterol of <40 mg/dL (1
mmol/L) in men and <50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL
cholesterol; 4. blood pressure (BP) of ≥130/85 mmHg or drug treatment for elevated BP; 5. FPG
of ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose.
Results
No notable differences were observed with respect to age, gender, and BMI between the two
groups. Both groups were age-, gender-, and BMI-matched (p>0.05) (Table 1). Body fat and
diastolic BP were found to be elevated in group B as compared to group A. Furthermore, liver
function enzymes (LFEs) were raised in group B.
Variable Group A (n=37) Group B (n=55) P-value
Age (years) 31.86 ± 13.8 34.69 ± 9.46 0.05
Gender M = 20; F = 17 M = 29; F = 26 -
Body mass index (kg/m2) 21.59 ± 3.19 22.67 ± 3.71 0.052
Body fat (%) 19.7 ± 0.963 22.88 ± 1.00 <0.05
Diastolic blood pressure (mmHg) 79.85 ± 2.33 91.22 ± 1.02 <0.05
HbA1c 5.23 ± 0.38 8.52 ± 1.82 <0.05
Serum alanine aminotransferase (IU/L) 14.43 ± 4.09 40.25 ± 5.562 <0.05
Serum alkaline phosphatase (IU/L) 140.46 ± 23.89 262.95 ± 35.31 <0.05
Triglyceride (mg/dl) 134.30 ± 51.19 166.26 ± 28.03 <0.05
Low-density lipoprotein (mg/dl) 79.44 ± 38.49 116.52 ± 9.62 <0.05
TABLE 1: Demographic and biochemical parameters
HbA1c: glycated hemoglobin
LCN-2 levels were compared for both the groups, and the results showed significantly raised
levels of LCN-2 (p<0.001) in group B (1896.90 ± 73.13 ng/ml SEM) compared to group A (263.58
± 15.66 ng/ml SEM) (Figure 2). Lastly, LCN-2 levels were evaluated and their correlation with
biochemical study parameters was performed using Pearson correlation as shown in Table 2.
The results showed that LCN-2 correlated moderately with T2DM markers and LFEs. For T2DM
markers, LCN-2 correlated moderately with fasting blood glucose (FBG) (r=0.377) and HbA1c
(r=0.341) (p<0.001). Simultaneously, for LFEs, LCN-2 correlated moderately with ALT (r=0.369)
and ALP (r=0.419) (p<0.001).
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FIGURE 2: LCN-2 levels for group A and group B
Box-plot graph for LCN-2 levels showing results of the Mann-Whitney U test for both groups. Group
B had significantly higher levels of LCN-2 with a significant p-value of less than 0.01
LCN-2: lipocalin-2
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Variable r-value P-value
Fasting blood glucose (mg/dl) 0.377 0.000
HbA1c 0.341 0.001
Alanine animotranferase 0.369 0.000
Alkaline phosphatase 0.419 0.000
HbsAg -0.0164 0.233
Cholesterol (mg/dl) 0.252 0.034
Triglycerides (mg/dl) 0.279 0.019
Low-density lipoprotein (mg/dl) 0.236 0.050
TABLE 2: Pearson correlation of LCN-2 levels with study parameters
LCN-2: lipocalin-2; HbA1c: glycated hemoglobin; HbsAg: hepatitis B surface antigen
Discussion
There are multiple associations with regard to the causes of T2DM, and abdominal obesity has
been found to be the leading cause of insulin resistance. Apart from causing T2DM, the
associated disrupted balance of hormones and glucose, i.e., the raised levels of insulin and
glucose along with elevated adipocyte cytokines, is thought to lead to abnormal lipid profiles,
functional atherosclerosis, hypertension, and vasculitis, all of which contribute towards
development and advancement of CVDs [19-21]. New theories about the character of adipose
tissue and the cytokines released by them have suggested correlations between adipokines such
as LCN-2 and their role in preventing systemic insulin resistance and, thus, MetS. However,
excess adipose tissue can alter the regulation of homeostasis, inflammation, and insulin
resistance and therefore lead to the aforementioned diseases [22,23].
Furthermore, it has been suggested that the constant state of inflammation due to increased
adipose tissue and increased level of cytokines initiate multiple processes in the body, which
become a leading cause of augmentation and evolution of atherosclerosis [24,25]. Patients
suffering from T2DM are prone to developing multiple diseases as complications; however,
most of the progression stems from baseline physiological damage caused by the biochemical
and hormonal imbalance. There have been multiple explanations as to why there is endothelial
damage in diabetics. Apart from being in a constant inflammatory state, patients with T2DM
also go through oxidative stress, both in turn leading to disturbance of the vasoprotective nitric
oxide (NO) pathway [26]. The basic thrust of this study was to evaluate subjects with both
T2DM and hepatic infections with regard to LCN-2, which is a cytokine that was previously
shown to be an indicator of the progression of the disease. Moderate correlation of LCN-2 with
liver functions such as ALT (r=0.369) and ALP (r=0.419) was seen in the current study,
confirming a positive relationship between LCN-2 levels and chronic infection. In a previous
study conducted in Germany in 2013 to assess the protective effects of LCN-2 in acute liver
damage, it was concluded that increased levels of LCN-2 are indicative of liver damage and
correlate with inflammation present in the liver [27].
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Furthermore, in addition to finding the links between the adipokine levels and infections, this
study also revealed increasing levels of LCN-2 in patients presenting with T2DM and
dyslipidemia. Researchers have evaluated the role of LCN levels with regard to HbA1c levels in
a few studies previously. A study conducted in Khartoum, Sudan found a positive correlation
(p<0.001) between LCN-2 and HbA1c as the latter’s levels were significantly elevated, compared
to the controls [28]. Raised LDL levels along with higher total cholesterol and serum creatinine
were also observed in disease-positive patients in comparison with controls (p<0.02).
We found an interrelation between LCN-2 levels and HbA1c (r=0.341) (p<0.001). LDL levels were
also found to be raised in the patient group; however, a significant association could not be
established in this regard. In multiple studies conducted previously, it has been established
that LCN-2 levels do correlate or contribute towards the development of heart disease or
cardiac hypertrophy. In a total cohort study conducted by Wu et al. in 2014, it was
demonstrated that LCN-2 levels had a positive relationship with age, BMI, and waist
circumference. Other variables measured to evaluate T2DM such as FBG, post-two-hour
glucose load, insulin resistance (homeostasis model), and HbA1c also showed associations.
Lipid profile and BP along with glomerular filtrate rate (eGFR) were also positively linked [29].
Of all these factors, BMI, waist circumference, FBG, and diastolic BP were considered to
evaluate MetS-like characteristics in our study.
It is evident from this study that patients who suffer from T2DM and chronic infections have
significantly elevated levels of serum LCN-2. However, our study is limited by the small sample
size that we were able to recruit. Yet, the trend shown in this pilot study showcases LCN-2
levels as a diagnostic tool to identify the risk in individuals who are not yet suffering from MetS
but are on the verge of getting it. The risk factors could be family history, central obesity, or a
sedentary lifestyle, where LCN-2 levels will provide an idea of the progression of the risk.
Similarly, in individuals diagnosed with MetS, LCN-2 levels will provide an idea of the
progression of the disease as well.
Conclusions
It may be concluded that high levels of circulating LCN-2 in subjects presenting with both
T2DM and hepatitis B may lead to a deranged inflammatory response. LCN-2 has proved to be a
reliable marker for multiple disease manifestations, such as T2DM, atherosclerosis,
dyslipidemia, and liver damage. There are protective qualities attributed to LCN-2 as well,
which, once utilized in future research, can be used to manipulate LCN-2 as a key factor in
immune modulation. The positive correlations can be used to further research and evaluate
where to consider LCN-2 as a considerable factor in risk factor assessment and management of
T2DM superimposed with hepatitis. Assessing the confounding factors such as race could be
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